Derlin‐1 exhibits oncogenic activities and indicates an unfavorable prognosis in breast cancer. (26th November 2019)

• Record Type: Journal Article
• Authors: Zeng, Jinsheng; Tian, Qiuhong; Zeng, Zhimin; Cai, Jing; Ye, Meiyu; Liu, Yaxiong; Liu, Anwen
• Is Part Of: Cell biology international. Volume 44:Number 2(2020)
• Page Start: 593
• Page End: 602
• Publication Date: 2019-11-26
• Subjects: breast cancer -- c‐Myc -- Derlin‐1 -- UBE2C; Cytology -- Periodicals; Cells -- Periodicals; 571.605
• DOI: 10.1002/cbin.11259
• Languages: English
• ISSNs: 1065-6995

Abstract

Abstract: Derlin‐1 is involved in the elimination of misfolded proteins and has been implicated in the progression of human cancers. However, its prognostic value and biological function in breast cancer remain unknown. Here, we show that Derlin‐1 is overexpressed in breast cancer and exhibits oncogenic activities via interaction with UBE2C. Increased expression of Derlin‐1 is correlated with lymph node metastasis, advanced clinical stage, and unfavorable overall survival in two cohorts containing over 1, 000 patients. Multivariate analyses by the Cox regression model suggest Derlin‐1 is an independent factor for poor prognosis. In vitro experiments demonstrate that Derlin‐1 expression is transcriptionally upregulated by c‐Myc. Ectopic expression of Derlin‐1 promotes breast cancer cell proliferation and migration, whereas the knockdown of Derlin‐1 results in the opposite phenotypes. Mechanistically, Derlin‐1 directly binds to UBE2C to increase the phosphorylation of AKT and ERK. The treatment of UBE2C siRNA markedly attenuates Derlin‐1‐mediated cell growth and migration. Collectively, our data suggest Derlin‐1 is a potential prognostic factor and functions as an oncogene in breast cancer.